GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-05-30| Licensing

Denali Taps PharmEnable to Discover AI-Based Small Molecule Candidates for Neurological Diseases

by Joy Lin
Share To

San Francisco, California-based Denali Therapeutics has reached out to Cambridge, UK-based PharmEnable to discover molecular candidates for neurodegenerative diseases with artificial intelligence (AI).

PharmEnable’s AI drug discovery platform will be paired with Denali’s expertise in delivering therapeutics across the blood brain barrier (BBB). The multi-year collaboration will include joint research programmers against undisclosed targets, which will be initiated over the next two years. 

Under the agreement, PharmEnable will receive an upfront payment as well as potential milestones. Small molecule candidates from the deal will be further developed and commercialized by Denali. 

Related article: Recounting 25 Years of Genetic and Human Diversity Discovery With deCODE Founder Kari Stefansson 

 

Denali Gives Updates on Neurodegenerative Collabs

 

Denali recently gave updates on its lead programs and multiple ongoing collaborations with Takeda, Sanofi, and Biogen. 

Denali’s flagship program, DNL310, is designed to treat MPSII, better known as Hunter syndrome. The treatment incorporates their BBB-crossing transport vehicle (TV) platform, and was reported to be on track to begin a “potentially registrational” Phase 2/3 study in the first half of 2022. 

The company’s second program DNL593 was developed in collaboration with Takeda. The investigational drug has begun a first-in-human study for GRN-related frontotemporal lobe dementia (FTD-GRN). 

Meanwhile, Denali’s partner Sanofi has initiated a Phase 2 study on their RIPK1 inhibitor DNL788 for patients with amyotrophic lateral sclerosis (ALS). The initiation of the trial triggered a milestone payout of $40 million from Sanofi. 

Denali is also looking forward to the start of late-stage studies on their LRRK2 inhibitor DNL151, which will be initiated by Biogen, under a collaboration estimated to be worth over $1 billion.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Looking at the Bigger Picture: 5 Key Takeaways from JPM 2025
2025-01-23
M&A
EY Predicts Smarter, Smaller M&A in Biotech and Pharma for 2025
2025-01-15
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
2025-01-10
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top